
|Videos|June 6, 2017
Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
Author(s)Jorge E. Cortes, MD
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
Advertisement
In this video, Jorge E. Cortes, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
Cortes presented the results of the study (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
2
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
3
119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)
4
What Does the Future Hold for Immune Effector Cell Therapies?
5




















































